Arcadia reported nine-month product revenue growth of $205,000, or 5%, but a net loss of $8.9 million and cash of $2.8 million. Management raised substantial doubt about its going-concern status and disclosed material weaknesses in financial controls.
RKDA · Arcadia Biosciences, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“We believe that our existing cash and cash equivalents will not be sufficient to meet our anticipated cash requirements for at least the next 12 months from the issuance date of these condensed consolidated financial statements, which raises substantial doubt about the Company’s ability to continue as a going concern, and the audit opinion on our 2025 audited consolidated financial statements includes a going concern explanatory paragraph regarding substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $0.17
- Open
- $0.19
- Day range
- $0.17–0.21
- 52-week closing range
- $0.15–3.84
- Average volume, 30 days
- 3.1M
- Short interest
- 116K · 1.9% of shares · 1.0 days
- Short volume, last session
- 50%
- Last earnings
- Nov 7, 2025
- Latest filing
- 10-Q · Nov 12
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Arcadia Biosciences reported Zola third-quarter 2026 revenue growth of 24% year over year and record quarterly sales, with net income of $1.8 million. A new 1L espresso formulation ships this month, while slim cans launch in early 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Packaged Foods — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RKDA
this stock
Arcadia Biosciences, Inc.
|
$1.03M | -91.5% | -3.7% | — | 1.9% |
|
JBS
Jbs N.V.
|
$39.01B | -17.8% | — | — | 1.3% |
|
KHC
Kraft Heinz Co
|
$29.50B | +2.8% | -0.1% | — | 8.7% |
|
GIS
General Mills Inc
|
$18.44B | -25.8% | +4.1% | — | 7.0% |
|
SJM
J M SMUCKER Co
|
$14.02B | +34.2% | +3.7% | — | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 22
Arcadia reported nine-month product revenue growth of $205,000, or 5%, but a net loss of $8.9 million and cash of $2.8 million. Management raised substantial doubt about its going-concern status and disclosed material weaknesses in financial controls.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RKDA | -23.8% | +4.6% | -81.5% | +7.2% | -91.5% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -18.3% | +10.9% | -75.9% | +12.4% | -96.4% |